MiNK Therapeutics, Inc. announced its financial results for the fourth quarter and full year 2024 on March 18, 2025. The company reported a cash balance of $4.6 million at the end of 2024.
Cash used in operations for the fourth quarter of 2024 was $1.7 million, a reduction from $3.0 million for the same period in 2023. For the full year 2024, cash used in operations decreased to $9.6 million, compared to $15.8 million in 2023.
The net loss for the full year 2024 was $10.8 million, or $2.86 per share, a significant improvement from a net loss of $22.5 million, or $6.54 per share, in 2023. Dr. Jennifer Buell, CEO, highlighted the company's disciplined capital management and strategic alliances as key drivers of progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.